You are viewing the site in preview mode

Skip to main content

Table 3b Risk factors for other herpes viruses and combined CMV/BKV viremia. Analyses were performed using Cox regression proportional hazards analysis. Covariates with a p < 0.100 were included in multivariate analyses

From: Transplant centers’ prophylaxis and monitoring strategies: a key determinant of current herpes and polyomavirus incidences – results from the DZIF kidney transplant cohort

 

Other herpes viruses (n = 31)

CMV/BKV co-viremia (n = 23)

 

Univariate

Multivariate

Univariate

Multivariate

 

HR

95%-CI

p

HR

95%-CI

p

HR

95%-CI

p

HR

95%-CI

p

Baseline data

            

Age (years)

1.013

0.986;1.039

0.353

   

0.994

0.965;1.023

0.670

   

Male gender

1.588

0.710;3.551

0.260

   

2.619

0.891;7.698

0.080

2.422

0.811;7.230

0.113

Deceased donor

0.912

0.437;1.904

0.807

   

3.217

0.952;10.870

0.060

3.043

0.886;10.451

0.077

ESP

0.922

0.347;2.834

0.987

   

0.303

0.041;2.246

0.243

   

Body mass index (kg/m2)

0.971

0.893;1.055

0.481

   

0.975

0.885;1.074

0.606

   

Previous transplantation

1.246

0.511;3.037

0.629

   

1.446

0.537;3.894

0.466

   

Pancreas-kidney

0.573

0.078;4.201

0.587

   

0.788

0.106;5.849

0.816

   

AB0i

0.548

0.075;4.021

0.554

   

0.760

0.102;5.651

0.789

   

CMV D+/R-

0.034

0.001;1.460

0.078

-

-

-

4.619

1.996;10.691

< 0.001

3.062

1.142;8.212

0.026

CMV R+

0.580

0.284;1.184

0.134

   

0.558

0.239;1.306

0.179

   

CMV D+

0.189

0.077;0.462

< 0.001

0.999

0.945;1.056

0.972

3.514

1.189;10.383

0.023

1.736

0.396;7.614

0.464

CMV prophylaxis1

0.207

0.100;0.430

< 0.001

0.224

0.107;0.469

< 0.001

3.395

0.796;14.481

0.099

1.205

0.199;7.285

0.724

Age class donor2

1.044

0.929;1.174

0.469

   

1.074

0.933;1.236

0.320

   

Delayed graft function3

1.274

0.549;2.957

0.573

   

0.196

0.026;1.456

0.111

   

Initial immunosuppression

Conditioning treatment4

1.707

0.836;3.484

0.142

   

1.524

0.669;2.530

0.324

   

Plasmapheresis

0.672

0.204;2.211

0.513

   

2.270

0.895;5.757

0.084

2.596

0.944;7.143

0.065

Thymoglobuline vs. BSX

1.466

0.632;3.402

0.373

   

1.778

0.701;4.510

0.226

   

Tacrolimus vs. Csa

0.591

0.271;1.291

0.187

   

2.172

0.502;9.403

0.299

   

Other events within first year post transplantation

Acute biopsy-proven rejection

1.330

0.458;3.855

0.600

   

1.261

0.370;4.299

0.711

   

TCMR

2.160

0.503;9.271

0.300

   

1.356

0.179;10.242

0.768

   

Bacterial infection

1.593

0.765;3.315

0.213

   

0.779

0.306;1.986

0.601

   

Fungal infection

4.732

1.432;15.637

0.011

5.443

1.636;18.111

0.006

0.048

0.000;4.367

0.602

   

Renal function 3 months after transplantation

eGFR in ml/min/1.73m2

0.981

0.958;1.003

0.094

0.983

0.961;1.005

0.132

0.998

0.989;1.006

0.573

   
  1. Abbreviations: CMV = Cytomegalovirus, BKV = BK-virus ESP = Eurotransplant Senior Program,, BSX = Basiliximab, Csa = Ciclosporine A, BPAR = biopsy proven acute rejection, TCMR= -cell-mediated rejection, eGFR = estimated glomerular filtration rate, D+/-= Donor positive/negative, R+/-=Recipient positive/negative; HR = Hazard ratio, 95%-CI = 95%-confidence-interval
  2. Other herpes viruses included HSV-1 (n = 15), HSV-2 (n = 6), VZV(n = 9), EBV (n = 5) and HHV-6 (n = 1).
  3. 1 Valganciclovir, 2 In 5-year intervals, 3 Need for hemodialysis within the first 7 days post-transplantation, 4 Rituximab, immunadsorption, plasmapheresis or thymoglobuline for induction therapy
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us